FGP
HALO icon

Freestone Grove Partners’s Halozyme HALO Stock Holding History

Freestone Grove Partners’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Sell
18,192
-2,527
-12% -$172K 0.01% 475
2026
Q1 		$1.34M Buy
20,719
+5,183
+33% +$365K 0.01% 425
2025
Q4 		$1.05M Buy
+15,536
New +$1.05M 0.01% 462
2025
Q3 		– Sell
-11,867
Closed -$617K – 795
2025
Q2 		$617K Buy
+11,867
New +$675K ﹤0.01% 496
2025
Q1 		– Sell
-6,839
Closed -$327K – 673
2024
Q4 		$327K Buy
+6,839
New +$351K ﹤0.01% 452

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Freestone Grove Partners's HALO Position: Q2 2026 in Review

Freestone Grove Partners reduced its Halozyme (HALO) stake by 12% in Q2 2026, selling an estimated $172K and leaving 18,192 shares worth $1.42M. The position accounts for 0.01% of the portfolio, ranked #475.

Freestone Grove Partners first reported a position in HALO in Q4 2024 and has held it in 5 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Freestone Grove Partners held 18,192 shares of Halozyme worth $1.42M as of Q2 2026.
  • Freestone Grove Partners sold 2,527 Halozyme shares in Q2 2026, an estimated $172K.
  • Halozyme made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #475 holding.
  • Freestone Grove Partners first reported a position in Halozyme in Q4 2024 and has held it in 5 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.